Medicare Part D: Prescription Drug Coverage

Medicare Part D is the federal program that provides outpatient prescription drug coverage to Medicare beneficiaries, operating through private insurers under contracts with the Centers for Medicare & Medicaid Services (CMS). This page covers the structure of Part D plans, how formularies and cost-sharing tiers work, the causal factors driving plan design, classification rules, and the tradeoffs embedded in the program's market-based architecture. Understanding Part D mechanics is essential for beneficiaries navigating annual plan selection, coverage gaps, and low-income subsidy eligibility.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps
• Reference Table or Matrix

Definition and Scope

Medicare Part D was established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA, Public Law 108-173) and took effect on January 1, 2006. The program extends prescription drug benefits to all Medicare-eligible individuals enrolled in Part A or Part B, covering approximately 51 million beneficiaries as of the enrollment figures published in the Medicare Statistics and Enrollment Data tracking by CMS.

Part D coverage is delivered exclusively through private plans — either standalone Prescription Drug Plans (PDPs) for beneficiaries in Original Medicare, or Medicare Advantage Prescription Drug plans (MA-PDs) that bundle drug coverage with medical benefits under Medicare Part C. CMS does not operate a direct government drug benefit; instead, it sets minimum benefit standards, approves plan formularies, and pays risk-adjusted subsidies to participating insurers.

The scope of covered drugs includes most FDA-approved prescription medications, certain biological products, and insulin. The program explicitly excludes specific drug categories, detailed in the Classification Boundaries section below.

Core Mechanics or Structure

Formularies and Tier Structure

Each Part D plan maintains a formulary — a list of covered drugs organized into cost-sharing tiers. CMS requires plans to cover at least 2 drugs in each therapeutic category, but the number of tiers and the drugs assigned to each tier vary by plan. A standard 5-tier structure assigns:

• Tier 1: Preferred generic drugs (lowest cost-sharing)
• Tier 2: Non-preferred generic drugs
• Tier 3: Preferred brand-name drugs
• Tier 4: Non-preferred brand-name drugs
• Tier 5: Specialty drugs (highest cost-sharing, typically 25–33% coinsurance)

Standard Benefit Structure (2024)

For 2024, the standard Part D benefit defined by CMS includes a $545 deductible (CMS Medicare Part D 2024 Fact Sheet). After the deductible, cost-sharing applies until the beneficiary's total drug spending reaches the catastrophic threshold.

The Inflation Reduction Act of 2022 (Public Law 117-169) restructured the benefit significantly for 2024 and 2025:

• The out-of-pocket (OOP) cap was set at $2,000 for 2025, eliminating the previous uncapped catastrophic phase for most beneficiaries (CMS IRA Part D Changes).
• Insulin costs were capped at $35 per month per covered product under Part D.
• Vaccine cost-sharing was eliminated for ACIP-recommended vaccines.

Premium Structure

The national base beneficiary premium for 2024 was set at $34.70 per month (CMS 2024 Announcement). Individual plan premiums vary above or below this base based on plan design and geography. High-income beneficiaries pay an Income-Related Monthly Adjustment Amount (IRMAA) surcharge on top of their plan premium, calculated on a sliding scale based on modified adjusted gross income from 2 years prior — a structure detailed further at Medicare Income-Related Adjustment (IRMAA).

Causal Relationships or Drivers

Market Competition as a Cost-Control Mechanism

Part D's architects embedded competitive bidding as the primary mechanism for controlling drug benefit costs. Plans submit annual bids to CMS, and beneficiaries' base premiums are tied to a national average of weighted plan bids. This creates an incentive for plans to negotiate lower drug prices with pharmacy benefit managers (PBMs) and manufacturers. The Congressional Budget Office, in its 2004 scoring of the MMA, projected lower costs partly because of this competitive structure.

Formulary Design Driven by Rebate Contracts

Plans frequently tier drugs based on manufacturer rebate arrangements negotiated through PBMs, not solely on clinical criteria. A drug with a large rebate may be placed on a preferred tier even if a therapeutically equivalent drug with a smaller rebate is clinically comparable. This creates formulary designs that reflect financial incentives as much as medical evidence.

Low-Income Subsidy (LIS) Enrollment Driving Access Disparities

The Extra Help / Low-Income Subsidy program (Medicare Low-Income Assistance Programs) provides full or partial premium and cost-sharing relief for beneficiaries at or below 150% of the federal poverty level. CMS automatically enrolls most dual-eligible beneficiaries (those on both Medicare and Medicaid). The gap between LIS-eligible and non-LIS-enrolled beneficiaries generates measurable adherence differences, as documented in Health Affairs and the Medicare Payment Advisory Commission (MedPAC) annual reports.

Classification Boundaries

Part D has explicit statutory exclusions. Under 42 U.S.C. § 1395w-102(e)(2), the following drug categories are excluded from Part D coverage regardless of medical necessity:

1. Drugs for weight loss or gain
2. Drugs for fertility enhancement
3. Drugs for erectile dysfunction
4. Drugs for cosmetic purposes or hair growth
5. Drugs that would be covered under Medicare Part A or Part B (e.g., certain chemotherapy agents, immunosuppressives administered in inpatient settings)
6. Prescription vitamins and minerals (except prenatal vitamins and fluoride)
7. Nonprescription (OTC) drugs
8. Barbiturates and benzodiazepines — although the Consolidated Appropriations Act of 2021 (Public Law 116-260) ended the benzodiazepine exclusion effective January 1, 2023.

Plans may offer supplemental coverage for some excluded categories through enhanced alternative benefit packages, but this is not standard.

Part B vs. Part D Drug Classification

The boundary between Part B and Part D drug coverage is a frequent source of billing complexity. As a rule: drugs administered by a provider in a clinical setting and billed under a medical benefit are Part B drugs; drugs a beneficiary self-administers at home are Part D drugs. Exceptions include oral anti-cancer drugs that are the chemical equivalent of an IV formulation, which may be covered under Part B depending on administration context.

Tradeoffs and Tensions

Access vs. Formulary Restriction

Plans are permitted to restrict access to drugs through prior authorization, step therapy requirements, and quantity limits. These tools lower plan costs but can delay access for beneficiaries whose clinicians have determined a specific drug is medically necessary. CMS establishes exception and appeals rights, but navigating them requires time and documentation — a structural burden that falls unevenly on beneficiaries with limited health literacy or support systems. The Medicare Appeals Process governs formal exception requests.

Plan Choice Complexity

The Medicare Plan Finder tool at CMS (Medicare Plan Finder: How to Use) lists hundreds of plan options in high-population states. Research published by the National Bureau of Economic Research has documented that beneficiaries frequently leave money on the table by not switching to lower-cost plans during annual open enrollment, a phenomenon attributed to switching costs and information overload rather than rational plan-specific preferences.

Stability vs. Annual Formulary Changes

Plans are permitted to alter formularies annually and — subject to CMS notice requirements — at mid-year for non-protected-class drugs. A drug covered at Tier 2 in one plan year may move to Tier 4 or be removed from formulary the following year, forcing beneficiaries either to absorb higher costs or switch plans during the Annual Enrollment Period (October 15 – December 7).

Common Misconceptions

Misconception 1: Part D is optional for all Medicare beneficiaries.
Part D enrollment is voluntary, but beneficiaries who do not enroll when first eligible and later want coverage face a Late Enrollment Penalty — a permanent premium surcharge of 1% of the national base beneficiary premium per month of uncovered delay, compounding indefinitely.

Misconception 2: Generic drugs are always available in Tier 1.
Formularies vary by plan. A generic drug may be placed in Tier 2 or even Tier 3 on certain plans, particularly if the plan has a rebate arrangement that favors a competing branded product. Checking formulary placement before enrollment is not optional — it is the mechanism by which costs are determined.

Misconception 3: The coverage gap ("donut hole") still exists.
The Inflation Reduction Act of 2022 effectively eliminated the standard coverage gap for 2024 by restructuring cost-sharing phases. Prior to the IRA, beneficiaries paid 25% coinsurance between the initial coverage limit and the catastrophic threshold. That phase now flows directly into reduced catastrophic coinsurance, and the $2,000 OOP cap for 2025 removes the unlimited exposure that characterized the original "donut hole."

Misconception 4: Part D covers all FDA-approved drugs.
As detailed in the Classification Boundaries section, the statute excludes specific drug categories regardless of FDA approval status, and individual plan formularies further restrict coverage to their approved drug lists.

Checklist or Steps

The following sequence describes the standard decision and enrollment process for Part D:

1. Confirm Medicare eligibility — Part D enrollment requires enrollment in Part A or Part B (Medicare Eligibility Requirements).
2. Identify the Initial Enrollment Period (IEP) — A 7-month window centered on the 65th birthday month, as defined under Medicare Enrollment Periods.
3. Compile a current medication list — Record the generic name, dosage, and frequency of all prescription drugs.
4. Use CMS Plan Finder — Enter the drug list and preferred pharmacies at medicare.gov/plan-compare to generate cost estimates by plan.
5. Verify formulary tier placement — Confirm each drug's tier and any prior authorization, step therapy, or quantity limit requirements in the specific plan's formulary document.
6. Review network pharmacies — Confirm whether preferred network pharmacies (which offer lower cost-sharing on many plans) are accessible.
7. Check LIS eligibility — Beneficiaries with income below 150% of the federal poverty level may qualify for Extra Help, which reduces or eliminates Part D premiums and cost-sharing.
8. Enroll through CMS or the plan — Enrollment can be completed at medicare.gov, by calling 1-800-MEDICARE, or directly through the plan.
9. Review annually during AEP — October 15 – December 7 each year is the window to switch plans for the following January 1 effective date.

Reference Table or Matrix

Part D Key Benefit Parameters: 2024 vs. 2025

Part D Plan Types Compared

The National Medicare Authority home provides orientation to the full Medicare program structure for beneficiaries beginning the research process.